Supplementary Information
Identification of genes associated with chemotherapy cross-resistance and treatment response in childhood acute lymphoblastic leukemia.
Supplemental Table 8: Overlap in genes discriminating multiple-drug cross-resistance and genes discriminating PRD-, VCR-, ASP- and DNR single-drug resistance.
Summary of the
overlapping gene probe sets with corresponding gene symbol (GS), map location
(ML) and ratio of the median log-transformed expression signal in
cross-resistant versus cross-sensitive ALL for multiple-drug cross-resistance
(Ratio). A gene probe set with a ratio of >1 is over-expressed and with a
ratio of <1 is under-expressed probe sets in cross-resistant ALL compared to
cross-sensitive ALL. The probe sets in overlap between multiple-drug
cross-resistance and single-drug resistance to PRD (A), ASP (B)
and DNR (C) alone are shown, highlighted in orange and yellow are genes
that are in common, no overlap was found with VCR alone. (D) Rows
indicate the overlapping genes (n) for single-drug
resistance PRD, VCR, ASP, DNR; and columns overlapping genes (n) and
percentages for cross-resistance (CR) and VCR-ASP discordant resistance (VA).
Overlap occurs in cases the total is not matching the sum of the genes. (1)
shows the numbers and the percentages if the significant set of genes
identified were compared and (2) shows the results if the analysis is done
using the same number of genes for multiple-drug resistance versus single-drug
resistance.
A
|
Probe Set ID |
Gene Name |
GS |
ML |
R/S ratio |
|
213061_s_at |
N-terminal
asparagine amidase |
NTAN1 |
16p13.13 |
0.60 |
|
203274_at |
coagulation
factor VIII-associated (intronic transcript) |
F8A |
xq28 |
0.60 |
|
202521_at |
CCCTC-binding factor (zinc finger protein) |
CTCF |
16q21-q22.3 |
0.66 |
|
218438_s_at |
endothelial-derived
gene 1 |
EG1 |
4p16 |
0.67 |
|
219679_s_at |
WW
domain containing adaptor with coiled-coil |
WAC |
10p12.1 |
0.67 |
|
208739_x_at |
SMT3
suppressor of mif two 3 homolog 2 (yeast) |
SUMO2 |
17q25 |
0.69 |
|
221547_at |
PRP18
pre-mRNA processing factor 18 homolog
|
PRPF18 |
10p14 |
0.77 |
|
208620_at |
poly(rC)
binding protein 1 |
PCBP1 |
2p13-p12 |
0.81 |
|
217729_s_at |
amino-terminal
enhancer of split |
AES |
19p13.3 |
0.82 |
|
205193_at |
v-maf musculoaponeurotic fibrosarcoma oncogene |
MAFF |
22q13.1 |
1.76 |
|
209795_at |
CD69
antigen (p60, early T-cell activation antigen) |
CD69 |
12p13-p12 |
2.14 |
|
36711_at |
v-maf musculoaponeurotic fibrosarcoma oncogene |
MAFF |
22q13.1 |
2.25 |
|
218589_at |
purinergic
receptor P2Y, G-protein coupled, 5 |
P2RY5 |
13q14 |
2.69 |
B
|
Probe Set ID |
Gene Name |
GS |
ML |
Ratio |
|
203274_at |
coagulation
factor VIII-associated (intronic transcript) |
F8A |
xq28 |
0.60 |
|
201140_s_at |
RAB5C,
member RAS oncogene family |
RAB5C |
17q21.2 |
0.63 |
|
201156_s_at |
RAB5C,
member RAS oncogene family |
RAB5C |
17q21.2 |
0.76 |
|
209604_s_at |
GATA
binding protein 3 |
GATA3 |
10p15 |
3.38 |
C
|
Probe Set ID |
Gene Name |
GS |
ML |
Ratio |
|
213061_s_at |
N-terminal
asparagine amidase |
NTAN1 |
16p13.13 |
0.60 |
|
202777_at |
soc-2
suppressor of clear homolog (C. elegans) |
SHOC2 |
10q25 |
0.61 |
|
202521_at |
CCCTC-binding factor (zinc finger protein) |
CTCF |
16q21-q22.3 |
0.66 |
|
218438_s_at |
endothelial-derived
gene 1 |
EG1 |
4p16 |
0.67 |
|
200059_s_at |
ras
homolog gene family, member A |
RHOA |
3p21.3 |
0.82 |
D
| |
|
1) |
multiple
resistance |
|
|
| |
|
Overlap |
CR (51) |
VA (200) |
% of CR |
% of VA |
|
single |
resistance |
PRD (42) |
13 |
0 |
25% |
0% |
|
VCR (59) |
0 |
15 |
0% |
8% |
|
ASP (54) |
4 |
36 |
8% |
18% |
|
DNR (22) |
5 |
0 |
10% |
0% |
| |
|
Total
(146) |
18 |
51 |
35% |
26% |
| |
|
|
|
|
|
|
| |
|
2) |
multiple resistance |
|
|
| |
|
Overlap |
CR (100) |
VA (100) |
% of CR |
% of VA |
|
single |
resistance |
PRD (100) |
21 |
0 |
21% |
0% |
|
VCR (100) |
1 |
10 |
1% |
10% |
|
ASP (100) |
14 |
36 |
14% |
36% |
|
DNR (100) |
19 |
1 |
19% |
1% |
| |
|
Total
(382) |
45 |
46 |
45% |
47% |
< Previous | Next >